How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

3,788 results for

Thromboembolic Disease in Pregnancy

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

61. Cohort study: Pregnant women with schizophrenia are at higher risk of pre-eclampsia, venous thromboembolism and adverse neonatal outcomes

in schizophrenic mothers confirm previous findings in the context of newer antipsychotic drugs and treatment practices. Women with schizophrenia should be counselled about increased risks and followed by a provider specialising in high-risk pregnancies. Strategies to address modifiable risk factors during pregnancy and the perinatal period are necessary. Special attention should be given to smoking cessation and control of blood pressure. Novel findings include increased rates of thromboembolic disease (...) Cohort study: Pregnant women with schizophrenia are at higher risk of pre-eclampsia, venous thromboembolism and adverse neonatal outcomes Pregnant women with schizophrenia are at higher risk of pre-eclampsia, venous thromboembolism and adverse neonatal outcomes | Evidence-Based Nursing We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our

2015 Evidence-Based Nursing

62. Comparative Effectiveness of Warfarin and Newer Oral Anticoagulants for the Long-term Prevention and Treatment of Arterial and Venous Thromboembolism

Thromboembolic diseases represent a major public health burden and are associated with significant morbidity and mortality. For over 50 years, vitamin K antagonists (VKAs) have been the mainstay of treatment and prophylaxis of thromboembolism. There are many indications for VKA, including primary prevention of systemic embolism in nonvalvular atrial fibrillation (AF) and mechanical prosthetic heart valves. Other indications include secondary prophylaxis following venous thromboembolism (VTE) and preventing (...) of Veterans Affairs Veterans Health Administration vitamin K antagonist venous thromboembolism 8 Warfarin and Newer Oral Anticoagulants: Long-term Prevention and Treatment of Arterial and VTE Evidence-based Synthesis Program EVIDENCE REPORT INTRODUCTION Thromboembolic diseases represent a major public health burden and are associated with significant morbidity and mortality. For more than 50 years, vitamin K antagonists (VKAs) have been the mainstay of treatment and prophylaxis of thromboembolism

2012 Veterans Affairs Evidence-based Synthesis Program Reports

63. Flowchart: Management of hypertension in pregnancy

investigations and fetal assessment Birth Inpatient or outpatient care Worsening maternal or fetal condition? Is birth indicated? Yes No No Yes Risk factors for preeclampsia • Previous history of preeclampsia • Family history of preeclampsia • Inter-pregnancy interval > 10 years • Nulliparity • Pre-existing medical conditions o APLS o Pre-existing diabetes o Renal disease o Chronic hypertension o Chronic autoimmune disease • Age > 40 years • BMI > 35 kg/m 2 • Multiple pregnancy • Elevated BP at booking (...) Flowchart: Management of hypertension in pregnancy Queensland Health State of Queensland (Queensland Health) 2016 http://creativecommons.org/licenses/by-nc-nd/3.0/au/deed.en Queensland Clinical Guidelines, Guidelines@health.qld.gov.au Queensland Clinical Guidelines www.health.qld.gov.au/qcg Management of hypertension in pregnancy Queensland Clinical Guidelines: Hypertensive disorders in pregnancy. Flowchart version: F15.13-2-V7-R20 Hypertension sBP = 140 mmHg and/or dBP = 90 mmHg Maternal

2016 Queensland Health

64. Hypertensive disorders of pregnancy

stable then every 30 minutes • Respiratory rate and patellar reflexes hourly • Temperature 2nd hourly • Continuous CTG monitoring if > 24 weeks (interpret with caution if : greater than, 10 years • Nulliparity • Pre-existing medical conditions o APLS o Pre-existing diabetes o Renal disease o Chronic hypertension o Chronic autoimmune disease • Age > 40 years • BMI > 35 kg/m 2 • Multiple pregnancy • Elevated BP at booking • Gestational trophoblastic disease • Fetal triploidy Maternal investigations (...) USS Ultrasound scan VTE Venous thromboembolism Definition of terms Expectant management Refers to prolongation of the pregnancy beyond 48 hours with maternal and fetal monitoring. 1 Multidisciplinary team May include as relevant to the clinical circumstances obstetrician, midwives, obstetric physician, anaesthetist, neonatologist/paediatrician experienced in the care of women with hypertension in pregnancy. Obstetrician Local facilities may differentiate the roles and responsibilities assigned

2016 Queensland Health

65. Guidelines for Weight Gain During Pregnancy: A Focused Practice Question

be gained during pregnancy. The search included: Turning Research into Practice (TRIP) database, National Guideline Clearinghouse, National Institute for Health Care Excellence (NICE), Society of Obstetricians and Gynaecologists of Canada (SOGC), Health Canada, Public Health Agency of Canada, Public Health Ontario, Centers for Disease Control and Prevention (CDC), Institute of Medicine, and the World Health Organization. The search was completed in November 2015 and is outlined in Appendix A. 4 (...) dystocia, caesarean section and thromboembolism. Refer to the data extraction table in Appendix C for further information regarding the SOGC guideline. 7 8. Synthesis of Findings ? The recommended amount of weight that a woman gains during her pregnancy is a range that is based on her pre-pregnancy body mass index (BMI). ? For women with a normal weight, 11.5 - 16 kg (25-35 lbs) is the recommended weight gain during pregnancy. ? These ranges are applicable to all women with singleton pregnancies

2016 Peel Health Library

66. Anaemia and iron deficiency in pregnancy and postpartum

for the Global Burden of Disease Study 2013. Lancet 2014;384:980-1004. (44) Milman N. Postpartum anemia II: prevention and treatment. Ann Hematol 2012;91:143-154. Anaemia, iron deficiency and pregnancy 2016 51 (45) Khalafallah AA, Dennis AE. Iron deficiency anaemia in pregnancy and postpartum: pathophysiology and effect of oral versus intravenous iron therapy. J Pregnancy 2012;2012:630519. (46) Breymann C, Bian XM, Blanco-Capito LR, Chong C, Mahmud G, Rehman R. Expert recommendations for the diagnosis (...) -2012 (60) Recommendations to prevent and control iron deficiency in the United States. Centers for Disease Control and Prevention. MMWR Recomm Rep 1998;47:1-29. (61) WHO. Iron Deficiency Anaemia: Assessment, prevention and control. (62) Good Clinical Practice Recommendations for Iron Deficiency Anemia in Pregnancy (IDA) in Pregnancy in India. The Journal of Obstetrics and Gynecology of India 2011;61:569-571. (63) Dudrick SJ, O'Donnell JJ, Matheny RG, Unkel SP, Raleigh DP. Stimulation

2016 Nordic Federation of Societies of Obstetrics and Gynecology

67. Antenatal care - uncomplicated pregnancy

are unsure about the safety of a medication during pregnancy, contact the on 0344 892 0909 for a patient-specific risk assessment. Assess and document the risk factors for venous thromboembolism including: History of thromboembolism. Thrombophilia (such as Factor V Leiden deficiency, Antiphospholipid syndrome, Prothrombin 20210, Protein C, protein S or antithrombin deficiencies). Other medical conditions (such as heart disease, sickle cell disease, systemic lupus erythematosus, obesity, anaemia, diabetes (...) are sufficient for a parous woman (having borne at least one viable offspring — usually after 24 weeks). Two ultrasound scans are usually offered during the course of an uncomplicated pregnancy: A dating scan (10–13 weeks). A fetal anomaly scan (18–20 weeks). Women with an uncomplicated pregnancy are usually offered screening for: Gestational diabetes. Hypertension in pregnancy and pre-eclampsia. Anaemia. Down's syndrome. Haemoglobinopathies (sickle cell disease and thalassaemia). Infections (asymptomatic

2019 NICE Clinical Knowledge Summaries

68. Thromboembolic Disease in Pregnancy

Thromboembolic Disease in Pregnancy Thromboembolic Disease in Pregnancy Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Thromboembolic (...) Disease in Pregnancy Thromboembolic Disease in Pregnancy Aka: Thromboembolic Disease in Pregnancy , Deep Vein Thrombosis in Pregnancy , Deep Venous Thrombosis During Pregnancy , DVT in Pregnancy , DVT Prophylaxis in Pregnancy II. Epidemiology Venous Thrombosis risk: 0.5 to 3 per 1000 pregnancies risk is increased 5 fold in pregnancy DVT occurs equally in all trimesters (but increases with each trimester and especially postpartum) III. Pathophysiology Hypercoagulation in pregnancy Procoagulants

2015 FP Notebook

69. Apixaban for the Treatment of Venous Thromboembolism in Patients With Cancer

Posted : October 26, 2018 See Sponsor: Fadoi Foundation, Italy Collaborator: University of Perugia, Italy Information provided by (Responsible Party): Fadoi Foundation, Italy Study Details Study Description Go to Brief Summary: Apixaban for the treatment of venous thromboembolism in patients with cancer: a prospective randomized open blinded end-point (PROBE) study Condition or disease Intervention/treatment Phase Venous Thromboembolism Drug: Apixaban Drug: Dalteparin Phase 3 Study Design Go (...) Apixaban for the Treatment of Venous Thromboembolism in Patients With Cancer Apixaban for the Treatment of Venous Thromboembolism in Patients With Cancer - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more

2017 Clinical Trials

70. Thrombosis Outcomes in Pediatric Venous Thromboembolism

biomarkers in children that develop poor VTE outcomes (such as recurrence, postthrombotic syndrome and post PE impairment ) after an initial VTE with those that do not develop such outcomes. Condition or disease Venous Thromboembolism Detailed Description: All newly diagnosed patients with a first radiologically confirmed thrombotic event (any site) diagnosed at Children's Medical Center, Dallas will be followed prospectively with global coagulation assessment over a 24-month period, and monitored (...) malignancy Pregnancy or immediate post-partum period (12 weeks after delivery) Sickle cell disease Known bleeding disorder Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03068923 Contacts Layout table for location contacts Contact: Kendra Malone, MPH

2017 Clinical Trials

71. Prophylaxis of Venous Thromboembolism in Advanced Lung Cancer (PROVE)

lung cancer and elevated D-dimer. Condition or disease Intervention/treatment Phase Venous Thromboembolism Lung Neoplasm Drug: Tinzaparin Sodium Phase 3 Detailed Description: Adult patients aged ≥ 18 years with stage IV lung cancer and elevated D-dimer will be randomized to the experimental or control group.Patients in the control group will receive usual care, patients in the experimental group will receive subcutaneous tinzaparin once daily for six months. Follow-up visit will take place (...) table for additional information Studies a U.S. FDA-regulated Drug Product: No Studies a U.S. FDA-regulated Device Product: No Keywords provided by Assistance Publique - Hôpitaux de Paris: Low-molecular-weight Heparin Tinzaparin Additional relevant MeSH terms: Layout table for MeSH terms Thromboembolism Venous Thromboembolism Lung Neoplasms Embolism and Thrombosis Vascular Diseases Cardiovascular Diseases Respiratory Tract Neoplasms Thoracic Neoplasms Neoplasms by Site Neoplasms Lung Diseases

2017 Clinical Trials

72. REduced Dose Versus Full-dose of Direct Oral Anticoagulant After uNprOvoked Venous thromboEmbolism.

, a reduced dose of DOAC will be non-inferior to a full dose of DOAC in terms of recurrent VTE during extended anticoagulation phase. Condition or disease Intervention/treatment Phase Venous Thromboembolism Drug: Reduced dose of DOAC Drug: Full dose of DOAC Phase 3 Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Estimated Enrollment : 2200 participants Allocation: Randomized Intervention Model: Parallel Assignment Intervention Model Description: The trial (...) anticoagulant-related bleeding Additional relevant MeSH terms: Layout table for MeSH terms Thromboembolism Venous Thromboembolism Embolism and Thrombosis Vascular Diseases Cardiovascular Diseases Rivaroxaban Apixaban Anticoagulants Factor Xa Inhibitors Antithrombins Serine Proteinase Inhibitors Protease Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action

2017 Clinical Trials

73. Distribution of Risk Factors for Venous Thromboembolism in Blood Donors

in the presence of cancer. The risk increases with the age for unclear reasons. There are also differences in the incidence according to ethnicity; however, data in subjects of European ancestry are scarce. Several studies have documented an association between thrombosis and ABO group. Specifically, non-O blood groups have a higher risk of myocardial infarction, angina, peripheral vascular disease, cerebral ischemia and venous thromboembolism than O. While there are numerous studies carried out in patients (...) who have already shown thromboembolic events, data on the incidence of risk factors in the healthy population are completely inadequate. Understanding the risk factors for venous thrombosis is necessary to maximize the prevention of this disease in individuals and groups of high-risk patients . For this purpose a self-administered questionnaire will be used. Data obtained by blood donors on exposure to risk factors will be used to set up a clinical score to validate in future studies to carry out

2017 Clinical Trials

74. Is Infection an Independent Risk Factor for Venous Thromboembolism? a Population-Based Case-Control Study. (PubMed)

/recent hospitalization with/without surgery, nursing home confinement, active cancer, trauma/fracture, leg paresis, prior superficial vein thrombosis, transvenous catheter/pacemaker, ischemic heart disease, congestive heart failure, chronic lung or renal disease, serious liver disease, asthma, diabetes mellitus, hormone therapy, and pregnancy/postpartum.A total of 513 cases (39.4%) and 189 controls (12.7%) had an infection in the previous 92 days (odds ratio, 4.5; 95% confidence interval, 3.6-5.5; P (...) Is Infection an Independent Risk Factor for Venous Thromboembolism? a Population-Based Case-Control Study. The independent association of recent infection with venous thromboembolism is uncertain. The study aims were to test both overall infection (site unspecified) and specific infection sites as potential risk factors for deep vein thrombosis and pulmonary embolism adjusting for other known venous thromboembolism factors.By using Rochester Epidemiology Project resources, we identified all

2017 American Journal of Medicine

75. Epidemiology of venous thromboembolism in Africa: a systematic review. (PubMed)

Epidemiology of venous thromboembolism in Africa: a systematic review. Essentials Venous thromboembolism (VTE) is among the three main causes of cardiovascular disease worldwide. This review is the first to summarize the epidemiology of VTE in African populations. The prevalence of VTE in Africa is high following surgery, in pregnancy and post-partum. At least one quarter of patients at risk of VTE in Africa are not receiving prophylaxis.Background Venous thromboembolism (VTE) is among (...) the three leading causes of cardiovascular disease worldwide. Despite its high burden, there has been no previous study summarizing the epidemiology of VTE in African populations. Hence, we conducted this systematic review to determine the prevalence, incidence and mortality associated with VTE, and to evaluate the use of VTE prophylaxis in Africa. Methods We searched PubMed, Scopus and African Journals Online to identify articles published on VTE in Africa from inception to November 19, 2016, without

Full Text available with Trip Pro

2017 Journal of thrombosis and haemostasis : JTH

76. Incidence and risk factors of venous thromboembolism during postpartum-period: a population-based cohort-study. (PubMed)

, primiparity, cesarean section, cardiac/renal diseases, and varicose veins were associated with an increased risk for postpartum venous thromboembolic events. The risk remained elevated for 180 days in women with thrombophilia, cesarean section, multiple pregnancy, varicose veins, and cardiac disease.The risk of venous thromboembolic events remained elevated compared with that of the nonpregnant women after the usually defined postpartum period (6 weeks). The results might assist in selecting women in need (...) , declining to two-fold immediately after that. Almost half of the venous thromboembolic events occurred between 43 and 180 days postpartum. The incidence of venous thromboembolic events was four-fold compared with that of nonpregnant women. Three venous thromboembolic events-related deaths occurred. Older age, higher body mass index, thrombophilia, multiple pregnancy, gestational diabetes, anemia, chorioamnionitis, threatening premature birth, in vitro fertilization with ovarian hyperstimulation

2017 Acta Obstetricia et Gynecologica Scandinavica

77. Low Molecular Weight Heparin (LMWH) vs Aspirin for Venous Thromboembolism (VTE) Prophylaxis in Orthopaedic Oncology

: 1) soft tissue sarcoma; 2) primary bone sarcoma; 3) metastatic bone disease. Within each of these groups, patients will be randomized to either aspirin or low molecular weight heparin (enoxaparin) for venous thromboembolism prophylaxis post operatively. Masking: None (Open Label) Primary Purpose: Prevention Official Title: Low Molecular Weight Heparin Versus Aspirin for Venous Thromboembolism Prophylaxis in Orthopaedic Oncology Actual Study Start Date : February 16, 2018 Estimated Primary (...) in and Exported from the U.S.: Yes Additional relevant MeSH terms: Layout table for MeSH terms Sarcoma Thromboembolism Venous Thromboembolism Hematoma Osteosarcoma Neoplasms, Connective and Soft Tissue Neoplasms by Histologic Type Neoplasms Embolism and Thrombosis Vascular Diseases Cardiovascular Diseases Hemorrhage Pathologic Processes Neoplasms, Bone Tissue Neoplasms, Connective Tissue Aspirin Heparin Heparin, Low-Molecular-Weight Dalteparin Anti-Inflammatory Agents, Non-Steroidal Analgesics, Non-Narcotic

2017 Clinical Trials

78. Comparison of Bleeding Risk Between Rivaroxaban and Apixaban for the Treatment of Acute Venous Thromboembolism

and rivaroxaban for the treatment of VTE. Condition or disease Intervention/treatment Phase Venous Thromboembolism Drug: Apixaban Drug: Rivaroxaban Phase 4 Detailed Description: VTE is the third leading cause of mortality by cardiovascular disease. Standard treatment for acute VTE uses a combination of parenteral Low-Molecular-Weight Heparin (LMWH) and oral vitamin K antagonists (VKA) for 3 months, and carries significant bleeding risk. The major and/or clinically-relevant non-major bleeding (CRNMB) event (...) Data (IPD) Sharing Statement: Plan to Share IPD: Undecided Layout table for additional information Studies a U.S. FDA-regulated Drug Product: No Studies a U.S. FDA-regulated Device Product: No Additional relevant MeSH terms: Layout table for MeSH terms Thromboembolism Venous Thromboembolism Embolism and Thrombosis Vascular Diseases Cardiovascular Diseases Rivaroxaban Apixaban Factor Xa Inhibitors Antithrombins Serine Proteinase Inhibitors Protease Inhibitors Enzyme Inhibitors Molecular Mechanisms

2017 Clinical Trials

79. Registry of Patients With Chronic Thromboembolic Pulmonary Hypertension in Novosibirsk Region

: Recruiting First Posted : November 21, 2017 Last Update Posted : November 21, 2017 See Sponsor: Novosibirsk Scientific Research Institute for Circulatory Pathology Information provided by (Responsible Party): Novosibirsk Scientific Research Institute for Circulatory Pathology Study Details Study Description Go to Brief Summary: There will be assessment of patients after acute pulmonary embolism for the development of CTEPH Condition or disease Intervention/treatment Chronic Thromboembolic Pulmonary (...) Registry of Patients With Chronic Thromboembolic Pulmonary Hypertension in Novosibirsk Region Registry of Patients With Chronic Thromboembolic Pulmonary Hypertension in Novosibirsk Region - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one

2017 Clinical Trials

80. Risk Factors of Venous Thromboembolism in Women During Hormonal Exposure

See Sponsor: University Hospital, Brest Information provided by (Responsible Party): University Hospital, Brest Study Details Study Description Go to Brief Summary: Young women have an increased risk of venous thromboembolism (VTE) during hormonale exposure (estrogen-containing pill or pregnancy). In order to detect women at higher risk of VTE during hormonal exposure, thrombophilia testing is often performed in order to adapt contraception methods and/or to increases thromboprophylaxy during (...) pregnancy. However, such practice is probably not accurate nor discriminent. Indeed, there are evidence that the impact of the familial history of VTE might be stronger than that of detectable inherited thrombophilia. The "FIT-H" study is a cross-sectional study comparing the prevalence of previous venous thromboembolism in first-degree relatives of women (propositi) who had a first episode of venous thromboembolism in association with hormonal exposure with the prevalence of previous venous

2017 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>